Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Directorate Change

8 Mar 2005 11:15

ReGen Therapeutics PLC08 March 2005 ReGen Therapeutics Plc REGEN THERAPEUTICS PLC APPOINTS ADDITIONAL NON-EXECUTIVE DIRECTOR 8 March 2005 ReGen Therapeutics Plc (the 'Company') today announces that it has appointed DrPeter Garrod to be a non-executive director of the Company with immediateeffect. Peter Garrod commented "I was introduced to a natural product for the potentialtreatment of Alzheimer's disease in 1998. I have followed and supported ReGenwith absolute dedication in their quest for a treatment for this debilitatingcondition. I have always been at the forefront of advances in technology in my own fieldand feel that my input will enhance the progress and development of ReGen andwill endeavour to support the best interests of the shareholders". Percy Lomax the Chairman and Chief Executive of the Company commented "I welcomePeter Garrod to the Board. As a major shareholder his backing for the Board isimportant, but I believe that his scientific and business experience, togetherwith his enthusiasm to produce a better treatment for Alzheimer's disease willbe major assets to ReGen". Dr Garrod was born on 24th October 1950 and was educated at the London Hospital,part of the University of London. He graduated with a BDS and is a LDS of theRoyal College of Surgeons. He has been the Senior Partner of the Bower DentalCentre, which specialises in advanced dental cosmetic surgery, for the last 18years. There are no details to be disclosed pursuant to paragraphs (f)(iii) to(viii) of Schedule 2 to the AIM Rules. Dr Garrod currently holds and is beneficially interested in 36,000,000 ordinaryshares of the Company representing 10.5% of the current issued share capital ofthe Company. For further information, please contact:Andrew MarshallMarshall Robinson RoeTel No 020 7960 6007 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
9th May 200610:51 amRNSResearch Update
15th Mar 200611:01 amRNSFinal Results
14th Feb 20067:00 amRNSAcquisition
8th Feb 200611:00 amRNSAcquisition
9th Jan 200611:00 amRNSResearch Update
10th Oct 200510:51 amRNSEGM Statement
28th Sep 20059:07 amRNSResearch Update
22nd Sep 20054:26 pmRNSHolding(s) in Company
20th Sep 200512:26 pmRNSHolding(s) in Company
15th Sep 20058:05 amRNSIssue of Equity
15th Sep 20058:00 amRNSShare Finance Facility
15th Sep 20057:48 amRNSInterim Results
6th Sep 200510:27 amRNSAcquisition of Rights
10th Aug 200511:03 amRNSGrant of US Patent
18th Jul 200510:20 amRNSChange of Adviser
27th Jun 20057:00 amRNSResearch Update
20th Jun 20057:01 amRNSResearch Update
13th Jun 200512:59 pmRNSDirector Shareholding
26th Apr 20051:08 pmRNSResult of AGM
26th Apr 200512:39 pmRNSAGM Statement
15th Mar 20054:53 pmRNSStatement re ADR's
8th Mar 200511:15 amRNSDirectorate Change
4th Mar 20057:00 amRNSResearch Update
14th Feb 200512:19 pmRNSHolding(s) in Company
14th Feb 20057:00 amRNSResearch Update
9th Feb 20057:00 amRNSFinal Results
7th Feb 20054:50 pmRNSHolding(s) in Company
1st Feb 200512:45 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.